Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Operating Leases (2019 - 2022)

Aytu Biopharma (AYTU) has disclosed Operating Leases for 4 consecutive years, with $2.4 million as the latest value for Q1 2022.

  • Quarterly Operating Leases fell 31.26% to $2.4 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Mar 2022, down 31.26% year-over-year, with the annual reading at $2.6 million for FY2021, 261.93% up from the prior year.
  • Operating Leases for Q1 2022 was $2.4 million at Aytu Biopharma, down from $2.7 million in the prior quarter.
  • The five-year high for Operating Leases was $3.5 million in Q1 2021, with the low at $211056.0 in Q4 2020.
  • Average Operating Leases over 4 years is $1.5 million, with a median of $804393.0 recorded in 2020.
  • The sharpest move saw Operating Leases tumbled 43.72% in 2020, then surged 1186.86% in 2021.
  • Over 4 years, Operating Leases stood at $375000.0 in 2019, then crashed by 43.72% to $211056.0 in 2020, then soared by 1186.86% to $2.7 million in 2021, then decreased by 11.41% to $2.4 million in 2022.
  • According to Business Quant data, Operating Leases over the past three periods came in at $2.4 million, $2.7 million, and $2.8 million for Q1 2022, Q4 2021, and Q3 2021 respectively.